© 2017

Immunotherapy of Hepatocellular Carcinoma

  • Tim F. Greten

Table of contents

  1. Front Matter
    Pages i-x
  2. Maria Tagliamonte, Maria Lina Tornesello, Franco M. Buonaguro, Luigi Buonaguro
    Pages 1-17
  3. Eishiro Mizukoshi, Shuichi Kaneko
    Pages 39-50
  4. Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro
    Pages 51-68
  5. Kohei Shigeta, Tai Hato, Yunching Chen, Dan G. Duda
    Pages 85-101
  6. Yi-Fan Zhang, Jessica Hong, Mitchell Ho
    Pages 103-119
  7. Tim F. Greten, Firouzeh Korangy
    Pages 121-135
  8. Back Matter
    Pages 163-167

About this book


In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials.

Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer.

Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.



Hepatocellular carcinoma liver cancer Immunotherapy tumor immunology Immune-based treatment

Editors and affiliations

  • Tim F. Greten
    • 1
  1. 1.National Cancer InstituteCenter for Cancer Research National Cancer InstituteBethesdaUSA

About the editors

Professor Tim F. Greten has received his training in Gastroenterology, Hepatology and Medical Oncology. He has been treating patients with hepatocellular carcinoma (HCC) for many years has been leading a number of clinical trials. Apart from his clinical expertise Professor Greten has been interested in the immunological aspects of HCC for more than 20 years. He is conducting basic research studies, which he published in the very top scientific journals including Nature, and Cancer Cell and is also a pioneer in immunotherapy studies in HCC. He published a number of different clinical trials testing different immune based approaches in HCC. Based on this medical and basic science background is considered on the world leaders in tumor immunology and immunotherapy of HCC.

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods